院内製剤化を目的としたグリベンクラミド坐剤の調製並びに有用性の検討

概要

論文の詳細を見る
Glibenclamide (GC) is widely used as an oral hypoglycemic drug in the treatment of non-insulin dependent diabetes mellitus (NIDDM). Since GC is usually taken for a long period, side effects and noncompliance are among the problems. In order to solve those problems, we prepared GC suppositories and examined their usefulness. Suppositories containing 4,20,and 40mg of GC were prepared and examined for drug release, drug absorption and blood glucose levels after the rectal administration of suppositories in rabbits. In the release test, GC suppositories released the drug continuously for 6 hours. The areas under the drug release-time curve (ADT) of 20 and 40mg GC suppositories were 3.5 and 6.2 times of 4mg GC suppositories respectively. The plasma concentrations after administration of 4 and 20mg GC suppositories showed about the same profiles for 6 hours. After administration of 40mg GC suppositories, the maximum plasma concentration (C_<max>) was observed at 2 hours. All the GC suppositories showed lower blood glucose levels compared with the control. The remainder of the area under the blood glucose concentrationtime curve between the control (RAUC) in the case of 40mg GC suppository was 1.3 times larger than that of the 4mg GC suppository. The GC suppositories sufficiently lowered the blood glucose levels. These results suggest that the GC suppositories should be useful in the hospital preparation for the treatment of NIDDM patients.
社団法人日本薬学会の論文
1998-09-01

院内製剤化を目的としたグリベンクラミド坐剤の調製並びに有用性の検討

スポンサーリンク

概要

著者

関連論文

スポンサーリンク